NEW YORK (GenomeWeb) – Oncgnostics, a Jena, Germany-based molecular diagnostic company, has out-licensed its GynTect cervical cancer test to Changchun Jienuo Medical Technology (CJMT), a subsidiary of Sinopharm Group in China.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.